Skip to main content
70°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Horizon Therapeutics
(NQ:
HZNP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Horizon Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
3 Stocks to Buy Low Today With High Hopes for Tomorrow
April 15, 2024
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
Via
InvestorPlace
Peering Into Horizon Therapeutics's Recent Short Interest
October 05, 2023
Via
Benzinga
Here's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth Today
October 04, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 28, 2023
Via
Benzinga
How Is The Market Feeling About Horizon Therapeutics?
September 18, 2023
Via
Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
September 13, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
$1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
September 12, 2023
Via
Benzinga
Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today
September 04, 2023
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
September 12, 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
September 11, 2023
Via
Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
September 05, 2023
On Friday, the U.S.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 05, 2023
Via
Benzinga
This Is What Whales Are Betting On Horizon Therapeutics
September 01, 2023
Via
Benzinga
Peering Into Horizon Therapeutics's Recent Short Interest
August 31, 2023
Via
Benzinga
P/E Ratio Insights for Horizon Therapeutics
August 30, 2023
Via
Benzinga
Is Amgen Stock a Top Buy and Hold?
August 21, 2023
The biotech checks several important boxes for long-term shareholders.
Via
The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
September 01, 2023
Tesla unveiled an updated Model 3, but also slashed Model S, X prices.
Via
Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
September 01, 2023
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).
Via
Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
September 01, 2023
The deal can now close in the fourth quarter.
Via
Investor's Business Daily
Is This the Green Light Biotech Stocks Have Been Waiting For?
August 31, 2023
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics.
Via
The Motley Fool
Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies'
August 29, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
August 28, 2023
Reuters
Via
Benzinga
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
August 28, 2023
Via
Benzinga
FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal
August 26, 2023
The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ: AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC...
Via
Benzinga
Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle
August 25, 2023
The FTC is pulling back somewhat on its effort to challenge the deal.
Via
Investor's Business Daily
Could Amgen Stock Help You Become a Millionaire?
August 16, 2023
Its pending acquisition of Horizon Therapeutics could make the company much bigger.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
August 07, 2023
Via
Benzinga
Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings
August 03, 2023
The massive biotech company also beat second-quarter expectations Thursday.
Via
Investor's Business Daily
Amgen To Report Q2 Earnings: Here's What To Expect
July 31, 2023
Amgen will report second-quarter 2023 results on Aug. 3, after the market close.
Via
Talk Markets
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.